Phase 1 evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV
Four GIST patients have entered this Phase 1 trial of PI3K inhibitor SF1126.
Four GIST patients have entered this Phase 1 trial of PI3K inhibitor SF1126.
Jonathan Fletcher presented results showing that sorafenib has superior in vitro potency.
Dr. Peter Reichardt presented a retrospective study wherein sorafenib showed significant clinical activity in resistant metastatic GIST patients.
After a courageous fight with cancer, Renate Croll, 65, of Millersburg, died June 17, 2009, at the home of her daughter in Pensacola, Fla.
Innovative project will allow GIST researchers worldwide to access GIST tissue linked to patient-provided clinical histories. For more information on the GIST Tissue bank read the official press release.
NIH is launching the first integrated, drug development pipeline to produce new treatments for rare and neglected diseases.
The state of Israel is small. The number of patients diagnosed as GIST patients is estimated at as little as 20 patients per year. The need of GIST patients and their families to obtain updated [...]
nterstitial cells of Cajal are pacemaker cells, similar to the pacemaker cells of the heart, which cause the heart to beat regularly.
The U.S. News & World Report has announced its Best Hospital rankings for 2008. Now in its 19th year, U.S. News judges hospitals, not on routine procedures, but in difficult cases across an entire specialty. Out of [...]
Often, in the LRG email community, members have been known to offer suggestions on everything from what to bring with you to the hospital to managing side-effects. Louise Ladd is one of those people and [...]